Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology
Joseph Mikhael, MD
Conference Coverage
Optimizing Sequencing of CAR T-Cell and Bispecific Therapies to Improve Multiple Myeloma Outcomes
01/05/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the...
01/05/2026
Oncology
Robert Orlowski, MD, PhD
Conference Coverage
Linvoseltamab Demonstrates Deep, Durable Responses as Frontline Myeloma Therapy: LINKER-MM4 Trial
12/17/2025
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Ran Reshef, MD, MSc
Conference Coverage
Relationship of Cilta-Cel Dose to PFS Outcomes for Patients With R/R Multiple Myeloma: Real-World Analysis
12/08/2025
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of...
12/08/2025
Oncology
Mitul Gandhi, MD
Conference Coverage
Daratumumab Added to Lenalidomide Maintenance Therapy Following Transplant Improves Depth and Durability of MRD Response for MM: AURIGA Study
12/07/2025
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide...
12/07/2025
Oncology
Joshua Richter, MD
Conference Coverage
Benefits of Dual Maintenance Therapy for Treating Multiple Myeloma Following Transplantation
08/20/2025
Joshua Richter, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in...
08/20/2025
Oncology
Noa Biran, MD
Conference Coverage
Evaluating the Role of Dual Maintenance Therapy for Patients With MM Following Transplant
08/20/2025
Noa Biran, MD
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a...
08/20/2025
Oncology
FDA Approval
FDA Approves Linvoseltamab-gcpt for Patients With Relapsed/Refractory Multiple Myeloma
07/02/2025
Emily Estrada
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved...
07/02/2025
Oncology
Amrita Krishnan, MD, FACP
Conference Coverage
Evaluating the Evolving Role of Stem Cell Transplantation for Patients With Multiple Myeloma
06/30/2025
Amrita Y. Krishnan, MD, FACP
Amrita Krishnan, MD, FACP, participated in a debate covering new data on the use of stem cell transplantation for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Amrita Krishnan, MD, FACP, participated in a debate covering new data on the use of stem cell transplantation for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Amrita Krishnan, MD, FACP,...
06/30/2025
Oncology
Tarun Wasil, MD
Conference Coverage
Evaluating Potential Treatment Strategies for Patients With Multiple Myeloma
06/28/2025
Tarun Wasil, MD
Tarun Wasil, MD, discusses treatment initiation and discontinuation for patients with multiple myeloma in various stages at the 2025 Great Debates in Hematologic Malignancies meeting.
Tarun Wasil, MD, discusses treatment initiation and discontinuation for patients with multiple myeloma in various stages at the 2025 Great Debates in Hematologic Malignancies meeting.
Tarun Wasil, MD, discusses...
06/28/2025
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use